Pricing Log in Create free account

Definium Therapeutics, Inc. (DFTX) vs Erasca, Inc. (ERAS)

Definium Therapeutics, Inc. and Erasca, Inc. are both Biotechnology companies. Definium Therapeutics, Inc. and Erasca, Inc. are of similar size ($4.9B and $4.8B). Across the 10 metrics below, Definium Therapeutics, Inc. leads on 5 and Erasca, Inc. on 5.

Valuation

Metric DFTX ERAS Biotechnology median
P/E n/m n/m 8.58
P/S n/m n/m 10.29
P/B 4.35 12.11 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA n/m n/m 0.67
EV/Sales n/m n/m 9.89
Earnings yield (9.50%) (6.75%) (31.56%)
Free cash flow yield (4.21%) (5.75%) (23.42%)

Profitability

Metric DFTX ERAS Biotechnology median
Gross margin 0.00% 0.00% 65.77%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.09%) (78.25%) (54.09%)
Return on assets (51.35%) (65.25%) (47.78%)
Return on invested capital 0.00% (203.13%) 0.00%

Growth

Metric DFTX ERAS Biotechnology median
Revenue growth (TTM) — — 5.83%
EPS growth (last fiscal year) (33.77%) 36.23% 29.36%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DFTX ERAS Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 6.95 8.29 4.80
Net debt to EBITDA 2.21 1.93 0.97

Dividend

Metric DFTX ERAS Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric DFTX ERAS Biotechnology median
Market cap 4.84b 4.91b 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack